Phibro Animal Health Stock Price, News & Analysis (NASDAQ:PAHC)

Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health declared a quarterly dividend on Monday, July 29th. Investors of record on Wednesday, September 4th will be paid a dividend of $0.12 per share on Wednesday, September 25th. This represents a $0.48 annualized dividend and a yield of 2.12%. The ex-dividend date is Tuesday, September 3rd. View Phibro Animal Health's Dividend History.

Phibro Animal Health Corp (NASDAQ:PAHC) posted its earnings results on Tuesday, August, 27th. The company reported $0.33 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.34 by $0.01. The firm had revenue of $203.90 million for the quarter, compared to the consensus estimate of $206 million. Phibro Animal Health had a return on equity of 29.99% and a net margin of 6.59%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the company earned $0.46 EPS. View Phibro Animal Health's Earnings History.

Phibro Animal Health is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Phibro Animal Health.

Phibro Animal Health issued an update on its FY20 earnings guidance on Tuesday, August, 27th. The company provided earnings per share guidance of $1.08 -1.15 for the period, compared to the Thomson Reuters consensus estimate of $1.66. The company issued revenue guidance of $833 -863 million, compared to the consensus revenue estimate of $857.96 million.

5 equities research analysts have issued 12 month price targets for Phibro Animal Health's shares. Their forecasts range from $18.00 to $42.00. On average, they expect Phibro Animal Health's share price to reach $26.60 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.

Media headlines about PAHC stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Phibro Animal Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Phibro Animal Health.

Phibro Animal Health saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 623,400 shares, a decline of 5.9% from the August 30th total of 662,400 shares. Based on an average daily volume of 225,000 shares, the short-interest ratio is currently 2.8 days. Approximately 3.1% of the company's shares are short sold. View Phibro Animal Health's Current Options Chain.

Some companies that are related to Phibro Animal Health include FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Genmab A/S (GMAB), Emergent Biosolutions (EBS), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE) and Biohaven Pharmaceutical (BHVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Phibro Animal Health investors own include Zynga (ZNGA), Trevena (TRVN), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Sonoma Pharmaceuticals (SNOA), Zynerba Pharmaceuticals (ZYNE), Zoetis (ZTS), Booking (BKNG), Ophthotech (OPHT) and RetailMeNot (SALE).

Phibro Animal Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Confluence Investment Management LLC (0.36%), Bridge City Capital LLC (0.13%), Nisa Investment Advisors LLC (0.05%), State of Alaska Department of Revenue (0.04%), Meeder Asset Management Inc. (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran, Jack Bendheim and Larry Lee Miller. View Institutional Ownership Trends for Phibro Animal Health.

PAHC stock was bought by a variety of institutional investors in the last quarter, including Bridge City Capital LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, Meeder Asset Management Inc., Confluence Investment Management LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Phibro Animal Health.

Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PAHC stock can currently be purchased for approximately $22.61.

Phibro Animal Health has a market capitalization of $914.57 million and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe.View Additional Information About Phibro Animal Health.

The official website for Phibro Animal Health is http://www.pahc.com/.

Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]